Amendment: SEC Form SCHEDULE 13G/A filed by Geron Corporation

$GERN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $GERN alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
RTW Investments, LP
 
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D., Managing Partner
Date:02/14/2025
 
Roderick Wong, M.D.
 
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D.
Date:02/14/2025
Get the next $GERN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GERN

DatePrice TargetRatingAnalyst
2/27/2025$3.50 → $2.00Buy → Neutral
B. Riley Securities
2/26/2025Buy → Neutral
H.C. Wainwright
11/5/2024$8.00Buy
H.C. Wainwright
10/16/2024Sector Outperform
Scotiabank
9/9/2024$7.00Outperform
Leerink Partners
4/30/2024$4.50Outperform → Neutral
Robert W. Baird
4/29/2024$10.00Buy
TD Cowen
3/15/2024$4.00 → $5.00Buy
Needham
More analyst ratings

$GERN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 225,000 shares of its common stock, consisting of stock options to purchase an aggregate of 150,000 shares of common stock and restricted stock units ("RSUs") representing an aggregate of 75,000 shares of common stock, to three newly hired employees as an inducement material to their acceptance of employment with the Company. The stock options and RSUs were granted on March 17, 2025. The stock options have an exercise price of $1.74 per share, which is equal to the closing price of Geron common stock on the grant date, have a 10-year term

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

    Approval across ESA ineligible and ESA relapsed/refractory non-del 5q patients with transfusion-dependent anemia due to LR-MDS, regardless of ring sideroblast (RS) status RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has granted marketing authorization for RYTELO® (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) wi

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Geron Corporation Announces Departure of Chief Executive Officer

    Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GERN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GERN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GERN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GERN
SEC Filings

See more

$GERN
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary
  • FDA Approval for RYTELO issued to GERON CORP

    Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GERN
Leadership Updates

Live Leadership Updates

See more
  • Geron Corporation Announces Departure of Chief Executive Officer

    Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that John "Chip" A. Scarlett, M.D., President, Chief Executive Officer and Chairman, will depart the company on March 31, 2025. While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately. Additionally, Elizabeth G. O'Farrell has been appointed as Chair of the Board. "It has been an honor to serve Geron over the last 14 years and participate in the development

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

    Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving innovative medical and scientific strategies that support RYTELO™ commercially and sustain important research and development opportunities for Geron. Dr. Eid has more than two decades of medical affairs, clinical development, and drug life-cy

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

    Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron's global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegler has more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations. "Jim brings to Geron an impressive track record of operationa

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GERN
Financials

Live finance-specific insights

See more
  • Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

    Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the fourth quarter and full year 2024 and recent business highlights. "2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly differentiated tre

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

    Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website f

    $GERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million

    RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma's synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation's (NASDAQ:GERN) RYTELO for $125 million in cash upfront. RYTELO was approved by the U.S. Food and Drug Administration in June 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelod

    $GERN
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GERN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more